Publications by authors named "Fafa Addo Boateng"

Claim this Profile
C
Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.
Cissy Kityo, Ivan K Mambule, Joseph Musaazi, Simiso Sokhela, Henry Mugerwa, Fafa Addo Boateng

Nat Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA).
Victoria Babirye Tumusiime, Eugene Ruzagira, Claire Norcross, Ingrid Eshun-Wilsonova, Jonathan Kitonsa, Fafa Addo Boateng

Wellcome Open Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans.
Rosie Mngqibisa, Yashna Singh, Catherine Orrell, Johan Lombaard, Sandy Griffith, Fafa Addo Boateng

South Afr J HIV Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
Cissy Kityo, Ivan K Mambule, Joseph Musaazi, Simiso Sokhela, Henry Mugerwa, Fafa Addo Boateng

Lancet Infect Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis